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Abstract. Acute lymphoblastic leukemia (ALL) with translo-
cation t(4;11) is a high-risk leukemia found in 60-85% of infants 
with ALL and is often refractory to conventional chemo-
therapeutics after relapse. To evaluate the efficacy of dietary 
resveratrol in vivo, 5-week-old NOD.CB17-Prkdcscid/J mice 
were fed a control diet or a diet containing 0.2% w/w resveratrol. 
After 3 weeks of dietary treatment, mice were engrafted with the 
human t(4;11) ALL line SEM by tail vein injection. Engraftment 
was monitored by evaluating the presence of human CD19+ 
cells in peripheral blood using flow cytometry. Relative to 
control diet, dietary resveratrol did not delay the engraftment 
of the leukemia cells. To determine if dietary resveratrol could 
increase efficacy of a chemotherapeutic agent, vincristine was 
injected intraperitoneally into leukemic mice fed the control 
or supplemented diet. Survival curves and monitoring the 
percentage of human leukemia cells in peripheral blood showed 
that resveratrol did not inhibit leukemia cell growth or influence 
the activity of vincristine. Mass spectrometric analysis of mouse 
serum revealed that the majority of resveratrol was present as 
glucuronidated and sulfated metabolites. These data do not 
support the concept that dietary resveratrol has potential as a 
preventative agent against the growth of high-risk t(4;11) ALL.
Introduction
Resveratrol (3,5,4'-trihydroxy-trans-stilbene) is a plant poly-
phenol that is present in grapes, red wine, blueberries, mulberries, 
and cranberries (1). In vitro studies have shown that resveratrol 
can inhibit proliferation and induce apoptosis in different types 
of cancer cells (1). In vivo, resveratrol has been reported to be 
an effective agent against breast, esophageal, lung, and colon 
cancers in animal models (2-6). Furthermore, resveratrol has 
been reported to sensitize neuroblastoma, glioblastoma, breast 
carcinoma, prostate carcinoma, leukemia, and pancreatic 
carcinoma cells to the actions of multiple traditional chemo-
therapeutic agents in vitro (7). At a molecular level, resveratrol 
has been reported to act as an antioxidant, inhibit transcription 
factor and kinase activation required for cell growth, and inhibit 
cell cycle progression (1,8-10).
High-risk acute lymphoblastic leukemia (ALL) with chro-
mosomal translocation t(4;11) has a poor prognosis for patients. 
A significant problem that limits survival of patients with t(4;11) 
ALL is the relapse of chemotherapy-resistant leukemia (11,12). 
The t(4;11) ALL is a pre-B cell leukemia found in 60-85% of 
infants with ALL. Several cell lines have been established 
from patients with t(4;11) ALL and these lines have been 
used in vitro to evaluate novel therapeutic agents (13-15). The 
nonobese diabetic x severe combined immunodeficient (NOD/
SCID) mouse model has been useful for evaluating different 
chemotherapeutic agents against leukemia (16-19). The SCID 
background has an absence of T and B lymphocyte popula-
tions and the NOD background provides reduced natural killer 
lymphocyte activity and absence of circulating complement 
that increase engraftment efficiency of human cells. The NOD/
SCID mouse model for leukemia mimics the human disease 
by homing to, and engrafting in, the bone marrow, spleen, and 
liver. The engraftment in organ sites correlates well with the 
presence of leukemia cells in the peripheral blood (20).
We have reported that resveratrol, as well as several other 
plant-derived polyphenols, such as carnosol, curcumin, and 
quercetin, are effective in vitro in inducing apoptotic cell death 
in t(4;11) and other ALL-derived cell lines (21-23). While resve-
ratrol has been shown to act by stimulating CD95- signaling in 
some cancer cells, the induction of apoptosis in the t(4;11) ALL 
lines by resveratrol occurred exclusively by disruption of mito-
chondrial homeostasis (21). These in vitro studies supported the 
concept that resveratrol has potential as a preventative agent 
against high-risk leukemia in vivo. In the current study, we 
determined whether dietary resveratrol prevented the engraft-
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ment and growth of the t(4;11) ALL cells in NOD/SCID mice. 
In addition, we tested the hypothesis that it could increase the 
efficacy of the chemotherapeutic agent vincristine; a standard 
chemotherapeutic agent used to treat this type of leukemia (24).
Materials and methods
Cells and reagents. SEM is a cell line that was established 
from a patient diagnosed with high-risk pre-B ALL containing 
the chromosomal translocation t(4;11)(q21;q23) (13). The cells 
were grown at 37˚C, 5% CO2 in RPMI-1640 (Invitrogen, 
Carlsbad, CA) that was supplemented with 10% fetal bovine 
serum (Sigma, St. Louis, MΟ), 50 IU/ml penicillin, 50 mg/l 
streptomycin, 0.25 mg/l amphotericin B, 1 mmol/l sodium 
pyruvate, and 2 mmol/l L-glutamine (Invitrogen). For injec-
tion into mice, SEM cells were collected and washed 2 times 
in Dulbecco's PBS without Ca2+ or Mg+ (Sigma). The cells 
were resuspended in PBS at a final concentration of 50x106 
cells/ml. 
Vincristine sulfate (Sigma) was dissolved in PBS and 
stored at -20˚C. To monitor leukemia burden in the blood, 
peripheral blood leukocytes were stained with phycoerythrin-
cyanin 7 (PE-Cy7)-conjugated anti-human CD19 and 
allophycocyanin-Cy7 (APC-Cy7) conjugated anti-mouse 
CD45 (Becton-Dickinson, San Jose, CA). Trans-resveratrol, 
tetra-deuterated trans-resveratrol (resveratrol-d4), resveratrol-
3-O-D-glucuronide, resveratrol-4'-O-D-glucuronide, and 
resveratrol-3-O-sulfate, and 1-cyclohexyluriedo-3-dodecanoic 
acid (CUDA) were purchased from Cayman Chemical Co. 
(Ann Arbor, MI). Sulfatase from Aerobacter aerogenes, 
β-glucuronidase (Type IX-A) from Escherichia coli, formic 
acid, glycerol, potassium 4-nitrophenyl sulfate, and 4-nitro-
phenyl β-D-glucuronide were obtained from Sigma. Ammonium 
hydroxide and LC/MS grades of methanol, acetonitrile, and 
water were purchased from Fisher Scientific (Fair Lawn, NJ). 
Normal mouse serum was obtained from United States 
Biological (Swampscott, MA).
Diets. Resveratrol (>98% pure) was purchased in bulk from 
Cayman Chemical Co. Rodent Diet 7013 (Harlan Teklad, 
Madison, WI), a commercial NIH-31 modified diet, was used 
as the base diet because it is similar in composition to the diet 
used by Jackson Laboratory for maintenance of the NOD.
CB17-Prkdcscid/J mouse strain. The diets used in the current 
study were prepared by Harlan Teklad. Diet 1 was the base 
diet (control) and diet 2 was the base diet containing 0.2% 
w/w resveratrol. A dietary concentration of 0.2% w/w resve-
ratrol is equivalent to approximately 300 mg/kg body weight/
day assuming a 20-g mouse and consumption of 3 g of food/
day. This dietary concentration was chosen to both minimize 
the risk for resveratrol-induced renal toxicity (25), and ensure 
that reasonable blood concentrations of resveratrol would reach 
the leukemia cells at engraftment sites. For the addition of the 
supplement, Rodent Diet 7013 was ground, the resveratrol was 
added, and the diet was repelleted. The control diet was also 
ground and repelleted so that the consistency of the food for 
each group was similar. The diets were γ-irradiated to sterilize 
and packaged in 2 kg vacuum sealed bags to reduce exposure to 
air. Diets were stored at -20˚C until use and fresh food was given 
to the mice weekly. 
Mice. Experimental procedures using mice were approved by 
the University of California, Davis Institutional Animal Care 
and Use Committee. Female NOD.CB17-Prkdcscid/J mice 
(5 weeks of age) were purchased from the Jackson Laboratory 
(Bar Harbor, ME, common name NOD/SCID). Upon arrival, 
the mice were randomly sorted into 2 groups (n=16 per group) 
and given the control diet or diet containing 0.2% w/w resve-
ratrol. Mice were given sterilized food and water ad libitum. 
Mice were housed under 12 h light-dark cycle, pathogen-free, 
temperature controlled conditions in ventilator racks at a 
University of California, Davis vivarium. Mice were weighed 
weekly. Weighing of mice and injections of leukemia cells or 
chemotherapeutic agent were performed in a biosafety cabinet to 
maintain pathogen-free conditions. Additions of food and water, 
and cage changes were performed in a laminar flow change-out 
cabinet. Mice were euthanized by carbon dioxide asphyxiation. 
Leukemia cell engraftment. After receiving the diets for 
3 weeks, each mouse was injected with 5x106 SEM cells 
(100 µl volume) through the tail vein. Approximately 2 weeks 
after injecting the leukemia cells, blood was collected from 
the tail artery of each mouse once per week using heparinized 
Microvette tubes (Sarstedt, Newton, NC). Blood from each 
mouse (approximately 50 µl) was transferred to a separate 
1.5 ml microfuge tube and the red blood cells were lysed using 
PharmLyse (Becton-Dickinson) according to the manufac-
turer's suggestions. The resulting peripheral blood leukocytes 
(PBLs) were stained with PE-Cy7 conjugated anti-human CD19 
and APC-Cy7 conjugated anti-mouse CD45. The cells were 
incubated with antibodies at room temperature for 20 min, 
washed in PBS containing 0.1% BSA and 7 mmol/l sodium 
azide (Sigma), and then fixed in 1% paraformaldehyde (Sigma) 
before analysis on a FACSCanto™ fluorescence-activated cell 
sorter (FACS) using FACSDiva™ software (Becton-Dickinson). 
Analysis of leukocytes was performed using appropriate scatter 
gates to exclude cellular debris and aggregated cells. The nega-
tive control was PBLs isolated from NOD/SCID mice that had 
not been injected with leukemia cells. The positive control was 
made by spiking an aliquot of PBLs (isolated from mice without 
leukemia) with SEM cells. Both the negative and positive control 
cells were stained with PE-Cy7 conjugated anti-human CD19 
and APC-Cy7 conjugated anti-mouse CD45 and used to set 
the gates for human CD19+ cells. Thirty thousand events were 
collected for each sample. Positive engraftment was defined as 
1% or greater human CD19+ cells present in the murine PBL 
population (18,19). 
Treatment with vincristine. All mice were injected intraperi-
toneally (i.p.) with vincristine at a concentration of 0.5 mg/kg 
body weight 3 times per week beginning approximately 4.5 
weeks after injection of leukemia cells (26). The total volume 
for each injection of vincristine was approximately 100 µl and 
was adjusted weekly according to the body weight of each 
mouse. All animals were fed the control or resveratrol diets 
during the chemotherapeutic treatment, and the percentage of 
human leukemia cells was monitored by flow cytometry as 
described above.
Liquid chromatography (LC) - tandem mass spectrometry 
(MS) analysis. Serum samples from NOD/SCID mice (n=5) 
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were prepared at the time of euthanization and stored at -70˚C 
until use. Serum from each mouse was separated into three 
25 µl aliquots for enzymatic digestion using a mock control 
(no enzyme), β-glucuronidase, or sulfatase. The serum samples 
were processed and analyzed as previously described (27).
Statistical analysis. Statistical analyses were performed with 
GraphPad software (GraphPad Software, Inc., San Diego, CA) 
and data are displayed as arithmetic means ± SEM. Event free 
survival (EFS) was used for comparisons between the treat-
ment groups, and was defined by overt clinical illness requiring 
euthanization, that included greater than 20% weight loss, 
lethargy, severe weakness, or inability to reach food or water 
for 24 h. The EFS was calculated beginning with the day of 
injection of the leukemia cells. Kaplan-Meier survival curves 
were used to determine differences in EFS by log-rank test. 
Differences in the body weights and percentage of CD19+ cells 
between the dietary groups were analyzed by 2-way ANOVA 
with Bonferroni posttests. The confidence interval for signifi-
cant differences was set at 95%. 
Results
Dietary resveratrol does not inhibit engraftment of leukemia. 
Mice were fed specialized diets for 3 weeks prior to injecting 
the leukemia cells to determine if dietary resveratrol delayed 
engraftment. Engraftment of SEM leukemia cells was 100% 
in both control and resveratrol fed mice. The rate of engraft-
ment as measured by the percentage of SEM leukemia cells 
in the PBL population in control and resveratrol fed mice was 
similar over a 4-week period after injection of the leukemia 
cells and prior to treatment with vincristine (Fig. 1, P=0.78). 
Dietary resveratrol does not sensitize the leukemia cells to 
vincristine. Mice were treated with vincristine at week 4 when 
the mean percentage of human leukemia cells in the mouse PBL 
population reached approximately 5.8±0.3% for the control 
group and 5.5±0.6% in the resveratrol fed group (Fig. 2). Mice in 
both feeding groups initially responded to the vincristine treat-
ment, resulting in a temporary decrease in leukemia burden. 
One mouse in the resveratrol fed group had a leukemia burden 
of approximately 10% in the peripheral blood and showed a 
delayed response to the vincristine treatment, resulting in 
the large standard error at week 5 (Fig. 2A). Removal of this 
mouse from the data analysis showed that vincristine treatment 
produced a similar reduction in the leukemia burden between 
the two dietary groups (Fig. 2B). Overall, there was no differ-
ence in the percentage of human leukemia cells in the mouse 
PBL population between the mice fed the control or resveratrol 
diets at weeks 5 and 6 after vincristine treatment (P=0.39, 
Fig. 2A, all data). After 2 weeks of treatment with vincristine, 
the leukemia burden began to increase and the mice became 
clinically ill.
Dietary resveratrol does not increase survival of leukemic 
mice. Mice were fed the control or resveratrol supplemented 
diets 3 weeks before injection of leukemia cells and throughout 
the experimental period. Survival was similar between the 
control and resveratrol supplemented mice (Fig. 3, P=0.74). 
The mice succumbed to the disease rapidly about 6 weeks after 
injection of the leukemia cells, and 2 weeks after treatment 
with vincristine. Mean body weights were similar between the 
Figure 2. Dietary resveratrol did not sensitize t(4;11) ALL cells to vincristine 
treatment. Mice were fed control or resveratrol supplemented diets (n=16 per 
group) for 3 weeks prior to injection of 5x106 SEM leukemia cells into the 
tail vein. Mice were monitored for engraftment of the leukemia by flow cyto-
metry beginning at 2 weeks after injection of the leukemia cells as described 
in Fig. 1. Arrows indicate the initiation of vincristine treatment at a dose of 
0.5 mg/kg body weight 3 times per week. (A), Represents data for all mice in 
each group. One mouse in the resveratrol fed group had a leukemia burden of 
approximately 10% and showed a delayed response to the vincristine treat-
ment, resulting in the large standard error at week 5. (B), Represents data 
shown in (A) minus the highly engrafted mouse, indicating that vincristine 
was similarly effective in reducing the leukemic burden in both groups. Data 
are presented as mean ± SEM. No differences in the percentage of CD19+ cells 
between the dietary groups was observed (2-way ANOVA, P=0.39 using all 
mice in each group).
Figure 1. Dietary resveratrol did not inhibit engraftment of t(4;11) ALL cells. 
Mice were fed control or resveratrol supplemented diets (n=16 per group) for 
3 weeks prior to injection of 5x106 SEM leukemia cells into the tail vein. Mice 
were monitored for engraftment of the leukemia by measuring the percentage 
of human CD19+ cells in the mouse peripheral blood leukocyte (PBL) popu-
lation by flow cytometry. Engraftment was defined as 1% or greater human 
CD19+ cells present in the murine PBL population. The graph represents the 
time after injection of the leukemia cell. The bars represent means ± SEM. No 
difference in the percentage of CD19+ cells was observed between the dietary 
groups (P=0.78).
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control and resveratrol supplemented mice before and after 
injection of the leukemia cells at 8 weeks of age (Fig. 4, P=0.09). 
Body weight loss was evident by 4-5 weeks after the injection 
of leukemia cells, and the mice continued to lose weight during 
the vincristine treatment. 
Dietary resveratrol was extensively metabolized to glucuro-
nides and sulfates. Due to the lack of anti-leukemia activity 
of resveratrol, the metabolism of resveratrol was evaluated by 
LC-MS in a subpopulation of surviving mice that were showing 
signs of clinical illness, but were still mobile and able to reach 
food (n=5). The mice were euthanized and the serum was either 
mock digested or digested with β-glucuronidase or sulfatase. 
The resulting increases in resveratrol aglycone after enzymatic 
digestion were used to determine the concentrations of glucuro-
nidated and sulfated metabolites. Incubation of serum with 
either β-glucuronidase or sulfatase increased the peak intensities 
of extractable resveratrol compared to the mock digested serum 
(Fig. 5A). The majority of the total resveratrol in the serum was 
present as metabolites. The mean percentage of resveratrol agly-
cone was 16±6%, whereas 57±9% and 27±6% of resveratrol was 
present as monoglucuronides and monosulfates, respectively 
(Fig. 5B). The 4-nitrophenyl glucuronide and sulfate conjugates 
(digestion controls) showed greater than 99% deconjugation 
efficiency. Deuterated resveratrol (surrogate) recoveries were 
45±6%, 50±2%, and 62±3% for the mock, β-glucuronidase and 
sulfatase digestions, respectively. 
Discussion
In human feeding studies, resveratrol has been used at levels 
up to 5 g/day, with some adverse results, including diarrhea, 
nausea, and abdominal pain, being reported at doses ranging 
from 2.5 to 5 g/day (28,29). In a 50-70 kg adult, the dose of 
5 g/day corresponds to 71-100 mg/kg body weight/day in 
humans. Due to the adverse responses in humans, it has been 
suggested that levels of dietary resveratrol for humans should 
not exceed 1 g/day. Toxicity studies have been performed in 
rats with oral administration of 100, 300, and 3000 mg/kg body 
weight/day and resveratrol was reported to have renal toxicity at 
3000 mg/kg body weight (25). In the present study with mice, 
we chose a dietary concentration of 0.2% w/w resveratrol that 
Figure 4. Body weights of the mice fed control or resveratrol supplemented diets 
were not different. Body weights of the mice were measured weekly. The mice 
were fed the control or resveratrol diets beginning at the age of 5 weeks and 
maintained on the diets throughout the experimental period. SEM leukemia 
cells were injected at the age of 8 weeks. Vincristine treatment was begun at 
about 12 weeks of age. The data represent means ± SEM. No differences in 
body weight were observed between the 2 dietary groups (P=0.09).
Figure 5. Dietary resveratrol was metabolized to glucuronidated and sulfated 
forms in leukemic mice. (A), Representative UPLC-MS/MS chromatograms 
of resveratrol isolated from serum collected from leukemic mice at the time 
of euthanization shows the metabolic profile of resveratrol after digestion 
with buffer (mock), β-glucuronidase, or sulfatase. Signal intensities for each 
mass transition are equivalent in the three panels. Deconjugation reactions 
increased peak areas of resveratrol relative to mock digestions, demonstrating 
the generation of glucuronide and sulfate conjugates in vivo. (B), Mean plasma 
concentrations of resveratrol aglycone and metabolites from 5 mice. The per-
centage of distribution of aglycone: glucuronides: sulfates was 16:57:27. The 
data represent means ± SEM.
Figure 3. Dietary resveratrol did not increase survival of the leukemic mice 
compared to the control diet. The mice were fed control or resveratrol supple-
mented diets 3 weeks prior to injection of the leukemia cells into the tail vein 
(n=16 per group). Treatment with vincristine was initiated at approximately 
28-30 days after injection of the leukemia cells. The mice were euthanized 
when they became clinically ill. Differences in survival after treatment began 
were determined by log-rank test. No difference in survival between the dietary 
groups was observed (P=0.74).
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is approximately 300 mg/kg body weight/day assuming a 20- 
mouse and consumption of 3 g of food/day diet. This dietary 
concentration was used to reduce renal toxicity in the mice, 
while ensuring there was a high potential of the resveratrol to 
reach the organs and tissues that harbored the leukemia cells. 
Despite the high amount (0.2% of the diet) of resveratrol given 
in the current study, there was no indication that its inclusion in 
the diet inhibited the engraftment or growth of high-risk t(4;11) 
leukemia in NOD/SCID mice. 
Studies have been performed in both humans and experi-
mental animals to determine the tissue distribution, excretion 
rates, and general bioavailability of resveratrol after its oral 
administration. In humans, after 25 mg of 14C-labelled resve-
ratrol was given as a single oral dose, the concentration of 
resveratrol peaked at approximately 500 ng/ml in the plasma 
(2 µmol/l) at 1 h, with a second peak of approximately 300 ng/ml 
(1.3 µmol/l) at 6 h (30). In these experiments, there was at least 
70% absorption of resveratrol and most of the oral dose was 
recovered in the urine. Although the plasma levels were low 
with the single oral dose of 25 mg, absorption was rapid and 
efficient and the plasma half-life of resveratrol and metabolites 
was calculated at 9.2 h. The major forms of resveratrol observed 
in this study were sulfate and glucuronide conjugates. More 
recently, humans given daily doses of 0.5, 1, 2.5, or 5 g for 
29 days showed maximal plasma concentrations of the resve-
ratrol aglycone at 0.19, 0.62, 1.45, and 4.24 µmol/l, respectively 
(28). However, the time of maximal plasma concentration of 
resveratrol aglycone in the human study was approximately 1 h 
and the majority of the resveratrol had been converted to the 
resveratrol-4'-O-glucuronide, resveratrol-3-O-glucuronide, and 
resveratrol-3-O-sulfate. 
The tissue distribution of orally administered resveratrol 
has been reported in animal models. In mice, a single oral 
dose of 14C-labelled resveratrol (5 mg/kg body weight) showed 
distribution in the duodenum, colon, liver, kidney, lung, spleen, 
heart, brain, and testis by 3 h, with the highest content in the 
duodenum (31). Longer term experiments utilizing rats showed 
the presence of resveratrol metabolites in the plasma after an 
8-week feeding of 300 mg resveratrol/kg body weight per 
day (32). The plasma, liver, kidney, urine, and feces contained 
mainly the sulfated and glucuronidated forms of resveratrol in 
these rats. By the end of the 8-week feeding study, the concentra-
tions of the different resveratrol conjugates in the plasma ranged 
from 0.37 to 7.46 mg/l (1.6-32.7 µmol/l). In the present study, 
only nmol/l levels of resveratrol aglycone were detected, but 
approximately 2 µmol/l glucuronide metabolites were present 
in the serum of leukemic NOD/SCID mice. Taken together, the 
SEM leukemia cells in the target organs (spleen, liver, and bone 
marrow) would have been mostly exposed to resveratrol metabo-
lites rather than the resveratrol aglycone. Further investigations 
will be required to evaluate the apoptotic activities of resveratrol 
metabolites against leukemia cells. However, our data suggest 
that the leukemia cells were not exposed to high enough levels 
of resveratrol aglycone and/or metabolites to induce leukemia 
cell death. 
The majority of in vitro studies on resveratrol focused on 
the study of the putative anti-cancer activity of this nutrient 
have been conducted using nonphysiological µmol/l concentra-
tions of the resveratrol aglycone. We submit that these types 
of in vitro experiments have limited value to elucidate the 
chemopreventive or therapeutic potential of resveratrol against 
leukemia in vivo. However, we note that resveratrol has been 
reported to have some efficacy in decreasing tumor burden and 
metastatic potential of a number of different cancers in rodent 
models (33). Resveratrol has been reported to inhibit metastasis 
of lung cancer and melanoma after intraperitoneal injection, and 
colon carcinoma metastasis after oral administration (34-36). 
Resveratrol has been reported to sensitize a number of cancers 
to chemotherapeutic agents in vitro and the mechanisms of this 
sensitization include down-regulation of multi-drug resistant 
protein expression, modulating the expression of cell survival 
proteins such as Bcl-2, down-regulating the transcription factor 
NF-κB, and cell cycle arrest (7). Reversal of doxorubicin resi-
stance in acute myeloid leukemia in vitro was reported to be 
mediated by down-regulation of the multi-drug resistant protein 
MRP-1, but only at a nonphysiological dose of 50 µmol/l (37). 
Limited data exist on the chemosensitizing effects of resveratrol 
in vivo. It was recently reported that resveratrol administered 
daily by gavage (at a dose of 40 mg/kg body weight) for 35 days 
significantly reduced the size of ectopic pancreatic tumors in 
nude mice, and that it potentiated the effects of gemcitabine in 
this model of pancreatic cancer (38). These experiments suggest 
that resveratrol may have potential as a chemopreventive agent 
depending upon the type of cancer and/or route of administra-
tion, and may be beneficial in the prevention of metastasis. 
High-risk t(4;11) ALL is an aggressive leukemia that has 
a poor prognosis due to development of chemotherapy resi-
stant cells. The t(4;11) ALL line SEM was established from 
a relapsed patient that had undergone chemotherapy (13). 
Engraftment of these cells in NOD/SCID mice was achieved 
rapidly within 2-3 weeks after injection of the leukemia cells. 
In vitro, the SEM cells are responsive to vincristine-induced 
apoptosis, but upon engraftment into NOD/SCID mice and 
treatment with vincristine, SEM cells revert to a vincristine-
resistant phenotype due in part by an increased expression of 
the multi-drug resistant protein P-glycoprotein (26). Dietary 
resveratrol did not sensitize these leukemia cells to vincri-
stine treatment, nor did this dietary nutrient inhibit the rapid 
engraftment and growth of SEM cells in the NOD/SCID mice. 
In summary, while dietary resveratrol may have potential as 
a chemopreventive agent against some cancers, the results 
presented in the current study suggest that this agent has 
minimal value with respect to the treatment or prevention of 
high-risk t(4;11) ALL in vivo. 
Acknowledgements
This work was supported by an award from National Institutes of 
Health, National Cancer Institute, award no. 1R21CA122117-01. 
The content is solely the responsibility of the authors and does 
not necessarily represent the official views of the National 
Institutes of Health. No conflicts of interest are present for any 
of the authors. USDA is an equal opportunity provider and 
employer.
References
  1. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, 
et al: Role of resveratrol in prevention and therapy of cancer: 
preclinical and clinical studies. Anticancer Res 24: 2783-2840, 
2004.
ZUNINO et al:  DIETARY RESVERATROL DOES NOT INHIBIT LEUKEMIA IN MICE2212
  2. Banerjee S, Bueso-Ramos C and Aggarwal BB: Suppression of 
7,12-dimethylbenz(a)anthracene-induced mammary carcino- 
genesis in rats by resveratrol: role of nuclear factor-κB, cyclo- 
oxygenase 2, and matrix metalloproteinase 9. Cancer Res 62: 
4945-4954, 2002.
  3. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, et al: Suppression 
of N-nitrosomethylbenzylamine (NMBA)-induced esophageal 
tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23: 
1531-1536, 2002.
  4. Lee EO, Lee HJ, Hwang HS, Ahn KS, Chae C, et al: Potent 
inhibition of Lewis lung cancer growth by heyneanol A from the 
roots of Vitis amurensis through apoptotic and anti-angiogenic 
activities. Carcinogenesis 27: 2059-2069, 2006.
  5. Liu HS, Pan CE, Yang W and Liu XM: Antitumor and immuno-
modulatory activity of resveratrol on experimentally implanted 
tumor of H22 in Balb/c mice. World J Gastroenterol 9: 1474-1476, 
2003. 
  6. Tessitore L, Davit A, Sarotto I and Caderni G: Resveratrol 
depresses the growth of colorectal aberrant crypt foci by affecting 
bax and p21(CIP) expression. Carcinogenesis 21: 1619-1622, 2000.
  7. Gupta SC, Kannappan R, Reuter S, Kim JH and Aggarwal BB: 
Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 
1215: 150-160, 2011.
  8. Colin D, Limagne E, Jeanningros S, Jacquel A, Lizard G, et al: 
Endocytosis of resveratrol via lipid rafts and activation of down-
stream signaling pathways in cancer cells. Cancer Prev Res 4: 
1095-1106, 2011.
  9. Li G, He S, Chang L, Lu H, Zhang H, et al: GADD45α and 
annexin A1 are involved in the apoptosis of HL-60 induced by 
resveratrol. Phytomedicine 18: 704-709, 2011.
10. Kartal M, Saydam G, Sahin F and Baran Y: Resveratrol triggers 
apoptosis through ceramide metabolizing genes in human K562 
chronic myeloid leukemia cells. Nutr Cancer 63: 637-644, 2011.
11. Faderl S, Kantarjian HM, Talpaz M and Estrov Z: Clinical signifi-
cance of cytogenetic abnormalities in adult acute lymphoblastic 
leukemia. Blood 91: 3995-4019, 1998.
12. Greaves MF and Wiemels J: Origins of chromosome transloca-
tions in childhood leukaemia. Nat Rev 3: 1-11, 2003.
13. Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, et al: 
The acute lymphoblastic leukaemia cell line SEM with t(4;11) 
chromosomal rearrangement is biphenotypic and responsive to 
interleukin-7. Br J Haematol 86: 275-283, 1994.
14. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC and Kersey JH: 
Human acute leukemia cell line with the t(4;11) chromosomal 
rearrangement exhibits B lineage and monocytic characteristics. 
Blood 65: 21-31, 1985.
15. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, et al: 
Growth factor requirements of childhood acute leukemia: esta-
blishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 
1987.
16. Baersch G, Mollers T, Hotte A, Dockhorn-Dworniczak B, Rube C, 
et al: Good engraftment of B-cell precursor ALL in NOD-SCID 
mice. Klin Padiatr 209: 178-185, 1997.
17. Borgmann A, Baldy C, von Stackelberg A, Beyermann B, 
Fichtner I, et al: Childhood ALL blasts retain phenotypic and 
genotypic characteristics upon long-term serial passage in NOD/
SCID mice. Pediatr Hematol Oncol 17: 635-650, 2000.
18. Liem NLM, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, 
et al: Characterization of childhood acute lymphoblastic leukemia 
xenograft models for the preclinical evaluation of new therapies. 
Blood 103: 3905-3914, 2004.
19. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, et al: 
The nonobese diabetic/severe combined immunodeficient 
(NOD/SCID) mouse model of childhood acute lymphoblastic 
leukemia reveals intrinsic differences in biologic characteristics 
at diagnosis and relapse. Blood 99: 4100-4108, 2002.
20. Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-
Nelemans HC, Willemze R, et al: Monitoring of engraftment and 
progression of acute lymphoblastic leukemia in individual NOD/
SCID mice. Exp Hematol 29: 322-329, 2001.
21. Dörrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces 
extensive apoptosis by depolarizing mitochondrial membranes 
and activating caspase-9 in acute lymphoblastic leukemia cells. 
Cancer Res 61: 4731-4739, 2001.
22. Dörrie J, Sapala K and Zunino SJ: Carnosol-induced apoptosis 
and downregulation of Bcl-2 in B-lineage leukemia cells. Cancer 
Lett 170: 33-39, 2001.
23. Kellner C and Zunino SJ: Nitric oxide is synthesized in acute 
leukemia cells after exposure to phenolic antioxidants and initially 
protects against mitochondrial membrane depolarization. Cancer 
Lett 215: 43-52, 2004.
24. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, 
et al: Augmented post-induction therapy for children with high- 
risk acute lymphoblastic leukemia and a slow response to initial 
therapy. N Engl J Med 338: 1663-1671, 1998.
25. Crowell JA, Korytko PJ, Morrissey RL, Booth TD and Levine BS: 
Resveratrol-associated renal toxicity. Toxicol Sci 82: 614-619, 
2004.
26. Zunino SJ, Storms DH and Ducore JM: Novel in vivo model of 
inducible multi-drug resistance in acute lymphoblastic leukemia 
with chromosomal translocation t(4;11). Cancer Lett 296: 49-54, 
2010.
27. Zunino SJ, Storms DH, Newman JW, Pedersen TL, Keen CL and 
Ducore JM: Resveratrol given intraperitoneally does not inhibit 
the growth of high-risk t(4;11) acute lymphoblastic leukemia 
cells in a NOD/SCID mouse model. Int J Oncol 40: 1277-1284, 
2012.
28. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, 
et al: Repeat dose study of the cancer chemopreventive agent 
resveratrol in healthy volunteers: safety, pharmacokinetics, and 
effect on the insulin-like growth factor axis. Cancer Res 70: 
9003-9011, 2010.
29. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, et al: 
Clinical trials of resveratrol. Ann NY Acad Sci 1215: 161-169, 
2011.
30. Walle T, Hsieh F, De Legge MH, Oatis JE and Walle UK: High 
absorption but very low bioavailability of oral resveratrol in 
humans. Drug Metab Dispos 32: 1377-1382, 2004.
31. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, 
et al: Distribution of [14C]-trans-resveratrol, a cancer chemopre-
ventive polyphenol, in mouse tissues after oral administration. 
Life Sci 72: 2219-2233, 2003.
32. Wenzel E, Soldo T, Erbersdobler H and Somoza V: Bioactivity 
and metabolism of trans-resveratrol orally administered to Wistar 
rats. Mol Nutr Food Res 49: 482-494, 2005.
33. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: 
the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006.
34. Kimura Y and Okuda H: Resveratrol isolated from Polygonum 
cuspidatum root prevents tumor growth and metastasis to lung 
and tumor-induced neovascularization in Lewis lung carcinoma-
bearing mice. J Nutr 131: 1844-1849, 2001.
35. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, et al: 
Resveratrol, a natural diphenol, reduces metastatic growth in an 
experimental cancer model. Cancer Lett 245: 144-148, 2007.
36. Weng YL, Liao HF, Li AF, Chang JC and Chiou RY: Oral admini-
stration of resveratrol in suppression of pulmonary metastasis of 
BALB/c mice challenged with CT26 colorectal adenocarcinoma 
cells. Mol Nutr Food Res 54: 259-267, 2010.
37. Kweon SH, Song JH and Kim TS: Resveratrol-mediated reversal of 
doxorubicin resistance in acute myeloid leukemia cells via down-
regulation of MRP1 expression. Biochem Biophys Res Commun 
395: 104-110, 2010.
38. Harikumar KB, Kunnumakkara1 AB, Sethi G, Diagaradjane P, 
Anand P, et al: Resveratrol, a multitargeted agent, can enhance 
antitumor activity of gemcitabine in vitro and in orthotopic mouse 
model of human pancreatic cancer. Int J Cancer 127: 257-268, 
2010.
